The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.
Ralph V. Boccia(Center for Cancer and Blood Disorders), Richard Lizambri(Amgen (United States)), David J. Kuter(Harvard University), Dominik Selleslag(National Institutes of Health), Mathias Rummel(Universitätsklinikum Gießen und Marburg), Ingrid Pabinger(Medical University of Vienna), Xuena Wang(Tianjin University of Traditional Chinese Medicine), B. Gail Macik(University of Virginia), Beng H. Chong(The University of Texas Southwestern Medical Center), Francesco Rodeghiero(Ospedale San Bortolo)
Cited by 2
Related Papers
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
|Clinical Infectious Diseases|2002|2.3k